| PRODUCT NDC | 0406-1516 | The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| PRODUCT TYPE NAME | BULK INGREDIENT | Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing. |
| NON PROPRIETARY NAME | MORPHINE SULFATE | The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product. |
| DOSAGE FORM NAME | POWDER | The translation of the dosage form Code submitted by the firm. |
| START MARKETING DATE | 4/1/2013 | This is the date that the labeler indicates was the start of its marketing of the drug product. |
| MARKETING CATEGORY NAME | BULK INGREDIENT | Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| LABELER NAME | SpecGx LLC | Name of Company corresponding to the labeler code segment of the Product NDC. |
| SUBSTANCE NAME | MORPHINE SULFATE | An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted. |
| ACTIVE NUMERATOR STRENGTH | 95 | |
| ACTIVE INGRED UNIT | kg/95kg | |
| DEA SCHEDULE | CII | This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. |